Shared posts

16 Jan 20:30

[ASAP] Small Molecule Benzothiophene with In Vivo Efficacy in a Mouse Model of Drug-Resistant Enterococcus faecium Infection

by Ricardo Gallardo-Macias, Riccardo Russo, Matthew Sherwood, Mark Jaskowski, Wissam Nasser, Pankaj Sharma, Margareta Tuckman, Eric Singleton, Hsin Pin Ho, Steven Park, Jimmy S. Patel, Amir George, David Perlin, Matthew D. Zimmerman, Nancy Connell, and Joel S. Freundlich

TOC Graphic

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.3c01846
16 Jan 20:28

[ASAP] DNA-Mediated Peptide Assembly into Protein Mimics

by Fangzhou Zhao, Martin Frandsen, Sabrina Capodaglio, and Hanadi F. Sleiman

TOC Graphic

Journal of the American Chemical Society
DOI: 10.1021/jacs.3c08984
16 Jan 15:22

Engineered probiotic overcomes pathogen defences using signal interference and antibiotic production to treat infection in mice

by Hackwon Do

Nature Microbiology, Published online: 16 January 2024; doi:10.1038/s41564-023-01583-9

Characterization of quorum sensing-regulated antibiotic production by Streptococcus salivarus and signal eavesdropping by Streptococcus pyogenes enables engineering of a probiotic strain to prevent pathogen signal eavesdropping and antibiotic degradation, and inhibit colonization.
15 Jan 19:38

The functional roles of short chain fatty acids as postbiotics in human gut: future perspectives

by Mangala Lakshmi Ragavan

Food Sci Biotechnol. 2023 Aug 28;33(2):275-285. doi: 10.1007/s10068-023-01414-x. eCollection 2024 Jan.

ABSTRACT

The significance of gut microbiome and their metabolites (postbiotics) on human health could be a promising approach to treat various diseases that includes inflammatory bowel diseases, colon cancer, and many neurological disorders. Probiotics with potential mental health benefits (psychobiotics) can alter the gut-brain axis via immunological, humoral, neuronal, and metabolic pathways. Recently, probiotic bacteria like Lactobacillus and Bifidobacterium have been demonstrated for SCFAs production, which play a crucial role in a variety of diseases. These acids could enhance the production of mucins, antimicrobial proteins (bacteriocins and peptides), cytokines (Interleukin 10 and 18) and neurotransmitters (serotonin) in the intestine to main the gut microbiota, intestinal barrier system and other immune functions. In this review, we discuss about two mechanisms such as (i) SCFAs mediated intestinal barrier system, and (ii) SCFAs mediated gut-brain axis to elucidate the therapeutic options for the treatment/prevention of various diseases.

PMID:38222911 | PMC:PMC10786766 | DOI:10.1007/s10068-023-01414-x

15 Jan 19:37

The Role of Attractive Non-Covalent Interactions in Peptide Macrocyclization

by Diego B Diaz

J Org Chem. 2024 Jan 13. doi: 10.1021/acs.joc.3c02084. Online ahead of print.

ABSTRACT

The efficiency of macrocyclization reactions relies on the appropriate conformational preorganization of a linear precursor, ensuring that reactive ends are in spatial proximity prior to ring closure. Traditional peptide cyclization approaches that reduce the extent of terminal ion pairing often disfavor cyclization-conducive conformations and can lead to undesired cyclodimerization or oligomerization side reactions, particularly when they are performed without high dilution. To address this challenge, synthetic strategies that leverage attractive noncovalent interactions, such as zwitterionic attraction between chain termini during macrocyclization, offer a potential solution by reducing the entropic penalty associated with linear peptides adopting precyclization conformations. In this study, we investigate the role of (N-isocyanoimino)triphenylphosphorane (Pinc) in facilitating the cyclization of linear peptides into conformationally rigid macrocycles. The observed moderate diastereoselectivity is consistent with the preferential Si-facial addition of Pinc, where the isocyanide adds to the E-iminium ion on the same face as the l-proline amide group. The resulting peptide chain reveals that the activated phosphonium ylide of Pinc brings the reactive ends close together, promoting cyclization by enclosing the carboxylate within the interior of the pentapeptide and preventing the formation of byproducts. For shorter peptides with modified peptide backbones, the cyclization mechanism and outcome are redirected, as nucleophilic motifs such as thiazole and imidazole can covalently trap nitrilium intermediates. The isolation of the intermediate in the unproductive macrocyclization pathway, along with nuclear magnetic resonance and density functional theory studies, provides insights into heterocycle-dependent selectivity. The Pinc-driven macrocyclization process has generated diverse collections of cyclic molecules, and our models offer a comprehensive understanding of observed trends, facilitating the development of other heterocycle-forming macrocyclization reactions.

PMID:38217516 | DOI:10.1021/acs.joc.3c02084

15 Jan 19:37

Maintenance of cell wall remodeling and vesicle production are connected in Mycobacterium tuberculosis

by Vivian Salgueiro

bioRxiv. 2023 Dec 20:2023.11.19.567727. doi: 10.1101/2023.11.19.567727. Preprint.

ABSTRACT

Pathogenic and nonpathogenic mycobacteria secrete extracellular vesicles (EVs) under various conditions. EVs produced by Mycobacterium tuberculosis ( Mtb ) have raised significant interest for their potential in cell communication, nutrient acquisition, and immune evasion. However, the relevance of vesicle secretion during tuberculosis infection remains unknown due to the limited understanding of mycobacterial vesicle biogenesis. We have previously shown that a transposon mutant in the LCP-related gene virR ( virR mut ) manifested a strong attenuated phenotype during experimental macrophage and murine infections, concomitant to enhanced vesicle release. In this study, we aimed to understand the role of VirR in the vesicle production process in Mtb . We employ genetic, transcriptional, proteomics, ultrastructural and biochemical methods to investigate the underlying processes explaining the enhanced vesiculogenesis phenomenon observed in the virR mutant. Our results establish that VirR is critical to sustain proper cell permeability via regulation of cell envelope remodeling possibly through the interaction with similar cell envelope proteins, which control the link between peptidoglycan and arabinogalactan. These findings advance our understanding of mycobacterial extracellular vesicle biogenesis and suggest that these set of proteins could be attractive targets for therapeutic intervention.

PMID:38187572 | PMC:PMC10769192 | DOI:10.1101/2023.11.19.567727

15 Jan 19:12

Conformationally constrained cyclic grafted peptidomimetics targeting protein-protein interactions

by Achyut Dahal

Pept Sci (Hoboken). 2023 Sep;115(5):e24328. doi: 10.1002/pep2.24328. Epub 2023 Jul 20.

ABSTRACT

Sunflower trypsin inhibitor-1 (SFTI-1) structure is used for designing grafted peptides as a possible therapeutic agent. The grafted peptide exhibits multiple conformations in solution due to the presence of proline in the structure of the peptide. To lock the grafted peptide into a major conformation in solution, a dibenzofuran moiety (DBF) was incorporated in the peptide backbone structure, replacing the Pro-Pro sequence. NMR studies indicated a major conformation of the grafted peptide in solution. Detailed structural studies suggested that SFTI-DBF adopts a twisted beta-strand structure in solution. The surface plasmon resonance analysis showed that SFTI-DBF binds to CD58 protein. A model for the protein-SFTI-DBF complex was proposed based on docking studies. These studies suggested that SFTI-1 grafted peptide can be used to design stable peptides for therapeutic purposes by grafting organic functional groups and amino acids. However, when a similar strategy was used with another grafted peptide, the resulting peptide did not produce a single major conformation, and its biological activity was lost. Thus, conformational constraints depend on the sequence of amino acids used for SFTI-1 grafting.

PMID:38188985 | PMC:PMC10769001 | DOI:10.1002/pep2.24328

15 Jan 18:18

High-throughput profiling of reactive cysteines

by Sarah Crunkhorn

Nature Reviews Drug Discovery, Published online: 12 January 2024; doi:10.1038/d41573-024-00008-4

High-throughput profiling of reactive cysteines
12 Jan 18:21

Design-rules for stapled peptides with in vivo activity and their application to Mdm2/X antagonists

by Arun Chandramohan

Nature Communications, Published online: 12 January 2024; doi:10.1038/s41467-023-43346-4

Stapled α-helical peptides are promising for targeting challenging targets such as transcription factors, but achieving sufficient cell permeability while avoiding off-target cleavage is difficult. Here, the authors present workflows for identifying stapled peptides against Mdm2(X) with in vivo activity and no off-target effects based on comprehensive investigations of their properties.
12 Jan 18:16

[ASAP] Cu-Catalyzed Azide–Alkyne–Thiol Reaction Forms Ubiquitous Background in Chemical Proteomic Studies

by Andreas Wiest and Pavel Kielkowski

TOC Graphic

Journal of the American Chemical Society
DOI: 10.1021/jacs.3c11780
11 Jan 18:17

[ASAP] Self-Assembly and Antimicrobial Activity of Lipopeptides Containing Lysine-Rich Tripeptides

by Anindyasundar Adak, Valeria Castelletto, Ana de Sousa, Kimon-Andreas Karatzas, Callum Wilkinson, Nikul Khunti, Jani Seitsonen, and Ian W. Hamley

TOC Graphic

Biomacromolecules
DOI: 10.1021/acs.biomac.3c01184
10 Jan 16:36

Delivery to, and Reactivation of, the p53 Pathway in Cancer Cells Using a Grafted Cyclotide Conjugated with a Cell-Penetrating Peptide

by Grégoire Jean-Baptiste Philippe

J Med Chem. 2024 Jan 4. doi: 10.1021/acs.jmedchem.3c01682. Online ahead of print.

ABSTRACT

Peptides are promising drug modalities that can modulate protein-protein interactions, but their application is hampered by their limited ability to reach intracellular targets. Here, we improved the cytosolic delivery of a peptide blocking p53:MDM2/X interactions using a cyclotide as a stabilizing scaffold. We applied several design strategies to improve intracellular delivery and found that the conjugation of the lead cyclotide to the cyclic cell-penetrating peptide cR10 was the most effective. Conjugation allowed cell internalization at micromolar concentration and led to elevated intracellular p53 levels in A549, MCF7, and MCF10A cells, as well as inducing apoptosis in A549 cells without causing membrane disruption. The lead peptide had >35-fold improvement in inhibitory activity and increased cellular uptake compared to a previously reported cyclotide p53 activator. In summary, we demonstrated the delivery of a large polar cyclic peptide in the cytosol and confirmed its ability to modulate intracellular protein-protein interactions involved in cancer.

PMID:38174919 | DOI:10.1021/acs.jmedchem.3c01682

10 Jan 16:34

Identification and engineering of potent cyclic peptides with selective or promiscuous binding through biochemical profiling and bioinformatic data analysis

by Thomas P Smith

RSC Chem Biol. 2023 Nov 14;5(1):12-18. doi: 10.1039/d3cb00168g. eCollection 2024 Jan 3.

ABSTRACT

As our understanding of biological systems grows, so does the need to selectively target individual or multiple members of specific protein families in order to probe their function. Many targets of current biological and pharmaceutical interest are part of a large family of closely related proteins and achieving ligand selectivity often remains either an elusive or time-consuming endeavour. Cyclic peptides (CPs) occupy a key niche in ligand space, able to achieve high affinity and selectivity while retaining synthetic accessibility. De novo cyclic peptide ligands can be rapidly generated against a given target using mRNA display. In this study we harness mRNA display technology and the wealth of next generation sequencing (NGS) data generated to explore both experimental approaches and bioinformatic, statistical data analysis of peptide enrichment in cross-screen selections to rapidly generate high affinity CPs with differing intra-family protein selectivity profiles against fibroblast growth factor receptor (FGF-R) family proteins. Using these methods, CPs with distinct selectivity profiles can be generated which can serve as valuable tool compounds to decipher biological questions.

PMID:38179194 | PMC:PMC10763615 | DOI:10.1039/d3cb00168g

10 Jan 16:34

A growing battlefield in the war against biofilm-induced antimicrobial resistance: insights from reviews on antibiotic resistance

by Liu Pai

Front Cell Infect Microbiol. 2023 Dec 19;13:1327069. doi: 10.3389/fcimb.2023.1327069. eCollection 2023.

ABSTRACT

Biofilms are a common survival strategy employed by bacteria in healthcare settings, which enhances their resistance to antimicrobial and biocidal agents making infections difficult to treat. Mechanisms of biofilm-induced antimicrobial resistance involve reduced penetration of antimicrobial agents, increased expression of efflux pumps, altered microbial physiology, and genetic changes in the bacterial population. Factors contributing to the formation of biofilms include nutrient availability, temperature, pH, surface properties, and microbial interactions. Biofilm-associated infections can have serious consequences for patient outcomes, and standard antimicrobial therapies are often ineffective against biofilm-associated bacteria, making diagnosis and treatment challenging. Novel strategies, including antibiotics combination therapies (such as daptomycin and vancomycin, colistin and azithromycin), biofilm-targeted agents (such as small molecules (LP3134, LP3145, LP4010, LP1062) target c-di-GMP), and immunomodulatory therapies (such as the anti-PcrV IgY antibodies which target Type IIIsecretion system), are being developed to combat biofilm-induced antimicrobial resistance. A multifaceted approach to diagnosis, treatment, and prevention is necessary to address this emerging problem in healthcare settings.

PMID:38188636 | PMC:PMC10770264 | DOI:10.3389/fcimb.2023.1327069

10 Jan 16:32

[ASAP] Improving Protein Expression, Stability, and Function with ProteinMPNN

by Kiera H. Sumida, Reyes Núñez-Franco, Indrek Kalvet, Samuel J. Pellock, Basile I. M. Wicky, Lukas F. Milles, Justas Dauparas, Jue Wang, Yakov Kipnis, Noel Jameson, Alex Kang, Joshmyn De La Cruz, Banumathi Sankaran, Asim K. Bera, Gonzalo Jiménez-Osés, and David Baker

TOC Graphic

Journal of the American Chemical Society
DOI: 10.1021/jacs.3c10941
09 Jan 20:52

D-alanine inhibits murine intestinal inflammation by suppressing IL-12 and IL-23 production in macrophages

by Hikaru Hashimoto

J Crohns Colitis. 2024 Jan 2:jjad217. doi: 10.1093/ecco-jcc/jjad217. Online ahead of print.

ABSTRACT

BACKGROUND AND AIMS: Free D-amino acids, which have different functions from L-amino acids, have recently been discovered in various tissues. However, studies on the potential interactions between intestinal inflammation and D-amino acids are limited. We examined the inhibitory effects of D-alanine on the pathogenesis of intestinal inflammation.

METHODS: We investigated serum D-amino acid levels in 40 patients with ulcerative colitis and 34 healthy volunteers. For 7 d, acute colitis was induced using dextran sulfate sodium in C57BL/6J mice. Plasma D-amino acid levels were quantified in mice with dextran sulfate sodium-induced colitis, and these animals were administered D-alanine via intraperitoneal injection. IFN-γ, IL-12p35, IL-17A, and IL-23p19 mRNA expression in the colonic mucosa was measured using real-time PCR. In vitro proliferation assays were performed to assess naïve CD4+ T cell activation under Th-skewing conditions. Bone marrow cells were stimulated with mouse macrophage-colony stimulating factor to generate mouse bone marrow-derived macrophages.

RESULTS: Serum D-alanine levels were significantly lower in patients with ulcerative colitis than in healthy volunteers. Dextran sulfate sodium-treated mice had significantly lower plasma D-alanine levels than control mice. D-alanine-treated mice had significantly lower disease activity index than control mice. IFN-γ, IL-12p35, IL-17A, and IL-23p19 mRNA expression levels were significantly lower in D-alanine-administered mice than in control mice. D-alanine suppressed naïve T cell differentiation into Th1 cells in vitro and inhibited the production of IL-12p35 and IL-23p19 in bone marrow-derived macrophages.

CONCLUSIONS: Our results suggest that D-alanine prevents dextran sulfate sodium-induced colitis in mice and suppresses IL-12p35 and IL-23p19 production in macrophages.

PMID:38165390 | DOI:10.1093/ecco-jcc/jjad217

09 Jan 17:11

Mining the microbiota for antibiotics

by Christine Beemelmanns

Nature Microbiology, Published online: 04 January 2024; doi:10.1038/s41564-023-01568-8

The antimicrobial agent epifadin, which is produced by the nasal commensal Staphylococcus epidermidis, has— despite its short half-life — broad-spectrum activity, including against Staphylococcus aureus.
09 Jan 17:10

A new class of macrocyclic peptides

by Krushnamurthy Pattanayakanahalli Henjarappa

Nature Chemical Biology, Published online: 08 January 2024; doi:10.1038/s41589-023-01507-y

Nature has evolved elegant enzymatic strategies to cyclize peptides, resulting in complex macrocyclic compounds with potent biological activities. A study illustrates the diverse chemical versatility of one such remarkable enzyme family, the cytochrome P450 macrocyclases, which form new biaryl crosslinks in ribosomal peptidic natural products.
08 Jan 18:33

Development and validation of cyclic peptide probe for gastric cancer based on phage display technique

by Seul Ki Yun, Seung Mok Yang, Moon Hwa Kwak, Jae Myung Park
Development and validation of cyclic peptide probe for gastric cancer based on phage display technique


Abstract

Cancer-targeting diagnostics should have a sensitive and specific binding affinity. To achieve this, biomarker development is critical. This study aimed to develop and validate a 7-mer cyclic peptide probe that can target gastric cancer. We developed this probe based on LGR5 (leucine-rich repeat-containing G-protein coupled receptor 5)-specific targeting, which is a marker for gastric cancer stem cells. An LGR5 targeting peptide sequence that was developed using phage display technology resulted in a cyclic peptide, C-YLASRVH-C (named YLA). We conjugated this peptide with fluorescent probes to validate its specific targeting ability for gastric cancer. The fluorescence-labeled YLA peptide exhibited 3.0-fold higher fluorescence intensity in a gastric cancer cell line (MKN45) than it did in a normal cell line (CCD841 cells). In contrast, pancreatic and colorectal cancer cells did not show significant fluorescence intensity with the YLA peptide. To verify its tumor-targeting affinity, we developed a control peptide, C-YLASAVH-C (named YLASA) using an ALA scanning experiment. Whole-body imaging of a gastric cancer xenograft model showed higher fluorescence intensity of tumors in the YLA peptide group than in the control peptide group. Moreover, ex vivo imaging of tumor tissues exhibited 6.8-fold higher fluorescence intensity in the YLA peptide group compared to that in the YLASA control peptide group. In conclusion, we confirmed that the YLA peptide probe functions as a specific diagnostic probe for gastric cancer. We anticipate that it will play a theranostic role through further development.

03 Jan 22:19

[ASAP] Metabolic Usage and Glycan Destinations of GlcNAz in E. coli

by Alexander Eddenden, Manoj K. Dooda, Zachary A. Morrison, Adithya Shankara Subramanian, P. Lynne Howell, Jerry M. Troutman, and Mark Nitz

TOC Graphic

ACS Chemical Biology
DOI: 10.1021/acschembio.3c00501
03 Jan 20:58

[ASAP] Noncovalent Conjugation of OVA323 to ELP Micelles Increases Immune Response

by Jolinde van Strien, Max Makurat, Ye Zeng, René Olsthoorn, Gregory F. Schneider, Bram Slütter, J. Andrew MacKay, Wim Jiskoot, and Alexander Kros

TOC Graphic

Biomacromolecules
DOI: 10.1021/acs.biomac.3c01091
03 Jan 20:53

[ASAP] Cleavage and Noncleavage Chemistry in Reactive Oxygen Species (ROS)-Responsive Materials for Smart Drug Delivery

by Teng Chi, Ting Sang, Yanjing Wang, and Zhou Ye

TOC Graphic

Bioconjugate Chemistry
DOI: 10.1021/acs.bioconjchem.3c00476
03 Jan 20:52

[ASAP] Inserting “OFF-to-ON” BODIPY Tags into Cytokines: A Fluorogenic Interleukin IL-33 for Real-Time Imaging of Immune Cells

by Abigail E. Reese, Fabio de Moliner, Lorena Mendive-Tapia, Sam Benson, Erkin Kuru, Thomas Bridge, Josh Richards, Jonathan Rittichier, Takanori Kitamura, Amit Sachdeva, Henry J. McSorley, and Marc Vendrell

TOC Graphic

ACS Central Science
DOI: 10.1021/acscentsci.3c01125
03 Jan 20:50

De novo development of small cyclic peptides that are orally bioavailable

by Manuel L Merz

Nat Chem Biol. 2023 Dec 28. doi: 10.1038/s41589-023-01496-y. Online ahead of print.

ABSTRACT

Cyclic peptides can bind challenging disease targets with high affinity and specificity, offering enormous opportunities for addressing unmet medical needs. However, as with biological drugs, most cyclic peptides cannot be applied orally because they are rapidly digested and/or display low absorption in the gastrointestinal tract, hampering their development as therapeutics. In this study, we developed a combinatorial synthesis and screening approach based on sequential cyclization and one-pot peptide acylation and screening, with the possibility of simultaneously interrogating activity and permeability. In a proof of concept, we synthesized a library of 8,448 cyclic peptides and screened them against the disease target thrombin. Our workflow allowed multiple iterative cycles of library synthesis and yielded cyclic peptides with nanomolar affinities, high stabilities and an oral bioavailability (%F) as high as 18% in rats. This method for generating orally available peptides is general and provides a promising push toward unlocking the full potential of peptides as therapeutics.

PMID:38155304 | DOI:10.1038/s41589-023-01496-y

03 Jan 20:50

Cytosolic sorting platform complexes shuttle type III secretion system effectors to the injectisome in Yersinia enterocolitica

by Stephan Wimmi

Nature Microbiology, Published online: 03 January 2024; doi:10.1038/s41564-023-01545-1

Using proximity labelling and single-particle tracking super-resolution microscopy, this study illuminates the initial steps of type III secretion and the path of T3SS effectors before their translocation into target cells.
03 Jan 20:49

2023 FDA approvals

by Asher Mullard

Nature Reviews Drug Discovery, Published online: 02 January 2024; doi:10.1038/d41573-024-00001-x

The FDA approved 55 novel therapeutics in 2023, the second highest count in the past 30 years.
02 Jan 17:10

Development of cyclic peptides that can be administered orally to inhibit disease targets

Nat Chem Biol. 2023 Dec 28. doi: 10.1038/s41589-023-01505-0. Online ahead of print.

NO ABSTRACT

PMID:38155305 | DOI:10.1038/s41589-023-01505-0

02 Jan 17:09

Development of stapled NONO‐associated peptides reveals unexpected cell permeability and nuclear localisation

by Reginald Young, Tiancheng Huang, Zijie Luo, Yaw Sing Tan, Amandeep Kaur, Yu Heng Lau
Development of stapled NONO-associated peptides reveals unexpected cell permeability and nuclear localisation

A stapling approach is reported to macrocyclise helical peptides derived from the insulin-like growth factor binding protein (IGFBP-3) and NONO (non-POU domain-containing octamer-binding protein), resulting in preferential localisation to the nucleus as observed by live confocal microscopy.


The non-POU domain-containing octamer-binding protein (NONO) is a nucleic acid-binding protein with diverse functions that has been identified as a potential cancer target in cell biology studies. Little is known about structural motifs that mediate binding to NONO apart from its ability to form homodimers, as well as heterodimers and oligomers with related homologues. We report a stapling approach to macrocyclise helical peptides derived from the insulin-like growth factor binding protein (IGFBP-3) that NONO interacts with, and also from the dimerisation domain of NONO itself. Using a range of chemistries including Pd-catalysed cross-coupling, cysteine arylation and cysteine alkylation, we successfully improved the helicity and observed modest peptide binding to the NONO dimer, although binding could not be saturated at micromolar concentrations. Unexpectedly, we observed cell permeability and preferential nuclear localisation of various dye-labelled peptides in live confocal microscopy, indicating the potential for developing peptide-based tools to study NONO in a cellular context.

02 Jan 17:08

Putting peptides on display

by Russell Johnson

Nature Chemical Biology, Published online: 20 December 2023; doi:10.1038/s41589-023-01494-0

Hiroaki Suga’s research has made substantial contributions to the development of artificial ribozymes and their application in mRNA display libraries. In 2006, Professor Suga help found the biopharmaceutical company PeptiDream Inc. He spoke to Nature Chemical Biology about the future of mRNA display libraries and the advantages they offer.
02 Jan 17:08

Development of cyclic peptides that can be administered orally to inhibit disease targets

Nature Chemical Biology, Published online: 28 December 2023; doi:10.1038/s41589-023-01505-0

Cyclic peptides can bind challenging disease targets, but their oral application is hindered by digestion and absorption issues. We developed a versatile method for the synthesis and functional screening of vast numbers of synthetic cyclic peptides and identified peptides with high inhibitory activity, stability and oral bioavailability in rats.